Lpath, Inc.

Jonathan Michael Wojciak

Roger A Sabbadini

William A Garland

Gordon B Mills

Genevieve Hansen

Rosalia Matteo

James Stephen Swaney

Tom Huxford

Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Compositions and methods for binding lysophosphatidic acid

Methods for designing optimized antibodies, including optimized humainized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them.

Antibody design using anti-lipid antibody crystal structures

Growing community of inventors

Encinitas, CA, United States of America

Jonathan Michael Wojciak